Effect of SmtO2 Guided Care on PONV (iMODIPONV) (iMODIPONV)

September 23, 2019 updated by: Lingzhong Meng, Yale University

Effect of Muscular Tissue Oxygen Saturation-Guided Management During Laparoscopic Hysterectomy on Postoperative Nausea and Vomiting: A Randomized Controlled Trial (iMODIPONV)

This randomized controlled trial is to investigate if SmtO2-guided management on top of the usual care, compared with the usual care only, during laparoscopic hysterectomy significantly reduces the incidence of PONV.

Study Overview

Detailed Description

Postoperative nausea and vomiting (PONV) remains prevalent despite the institution of various prophylactic measures. The incidence of PONV in female patients undergoing laparoscopic gynecological surgery is up to 50% with and 70% without the administration of antiemetics, respectively. The consequences of PONV range from patient discomforts, postoperative complications, prolonged hospitalization, to increased health care costs. Among the multiple risk factors, suboptimal gastrointestinal (GI) perfusion or oxygenation may be responsible for some cases of PONV; however, this speculation remains to be confirmed.5 Optimal tissue oxygenation, the balance between tissue oxygen consumption and supply, is essential for the integrity of any tissue bed that is metabolically active. However, GI oxygenation cannot be directly and continuously monitored in patients at this time. Whether there is an organ which can be used as a surrogate of the GI system, meaning that the tissue oxygenation of this surrogate organ not only can be monitored and that it also correlates with that of the GI system, is an intriguing question. Currently, tissue oxygenation can be measured using near-infrared spectroscopy (NIRS) in patients. The recent advancements of this technology enable the accurate monitoring of the oxygenation within many tissue beds depending on the location of the oximetry probe.

The recent cohort study demonstrated that there is a close relationship between muscular tissue oxygen saturation (SmtO2) and PONV in patients undergoing robotic laparoscopic hysterectomy (manuscript accepted and in production). Multiple thresholds based on threshold, AUC, and multivariable analyses are able to differentiate the risk of PONV. The following SmtO2 thresholds were found to correlate with a reduced risk of PONV: 20% above baseline; while the following thresholds correlate with an increased risk of PONV: 5% below baseline, 15% below baseline, and 20% below baseline, < 70%, < 65%, and < 60%. Taken together, our study suggests the potential therapeutic targets for PONV prophylaxis may be to maintain SmtO2 > 70% and above baseline.

In this study, the investigators aim to investigate if intraoperative care guided by SmtO2 monitoring reduces the incidence of PONV after laparoscopic hysterectomy.

Study Type

Interventional

Enrollment (Actual)

800

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beijing
      • Beijing, Beijing, China
        • Peking University Third Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Age 18-65 years
  2. Non-smoker
  3. ASA I-III
  4. Elective laparoscopic procedure involving hysterectomy

Exclusion Criteria:

  1. Refuse to participate
  2. Emergent surgery
  3. Bowel resection planned
  4. Vaginal or abdominal (open) hysterectomy
  5. Chemotherapy or radiotherapy before surgery
  6. Significant neuro, cognitive, or psychologic disease: stroke with neurologic deficit, dementia, schizophrenia, or any condition that makes meaningful postoperative follow-ups impossible
  7. Significant cardiovascular disease: low-output cardiac failure defined as a preoperative left ventricular ejection fraction < 30%, active coronary artery disease, symptomatic valvular disease, symptomatic arrhythmia with or without pacemaker and/or AICD placement
  8. Significant pulmonary disease: COPD requiring home oxygen therapy, severe asthma requiring steroid treatment, other pulmonary conditions requiring home oxygen therapy
  9. Severe hepatic dysfunction being evaluated for liver transplantation or with a Child-Pugh Class C classification
  10. Severe renal dysfunction requiring renal replacement therapy
  11. Muscular pathologies such as dystrophy, atrophy, and weakness
  12. Skin conditions incompatible with the adhesive oximetry probe (e.g., delicate or tattooed skin)
  13. Current or previous smoker
  14. ASA Physical Score ≥ IV

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
In addition to usual care during surgery, the intraoperative management will be additionally managed based on the guidance of muscular tissue oxygen saturation and non-invasive hemodynamic monitoring.
Muscular tissue oxygen saturation monitored at flank and arm will be maintained > 70% (absolute measurement) and > baseline throughout the entire procedure.
No Intervention: Control
Patients will receive the usual care. Muscular tissue oxygen saturation and non-invasive hemodynamic monitoring will be used but blinded to care givers.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of PONV within 24 hours after surgery
Time Frame: up to 24 hours

Nausea: Nausea is defined as a subjective unpleasant sensation associated with the urge to vomit.

Retching: Retching is defined as the labored, spastic, and rhythmic contraction of chest and abdominal muscles without expulsion of gastric contents.

Vomiting: Vomiting is defined as the forceful expulsion of any gastric contents from the mouth.

PONV: PONV refers to the occurrence of nausea, retching, and/or vomiting.

up to 24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of early PONV
Time Frame: up to 6 hours
The incidence of PONV during postoperative 0-6 hours. The diagnostic criteria for early PONV are the same as above (outcome 1).
up to 6 hours
Severity of postoperative pain
Time Frame: up to 24 hours
Postoperative pain intensity at rest and with movement expressed using NRS 0-10 (0 = no pain; 10 = worst pain) at 2, 6, and 24 h depending on the time to discharge
up to 24 hours
Time of GI recovery
Time Frame: up to 48 hours
Time to GI recovery (time to first flatus, bowel motion, and/or time to tolerate oral diet, in hours)
up to 48 hours
Overall quality of recovery based on QoR-15 questionnaire
Time Frame: up to 24 hours

Postoperative quality of recovery

(using the QoR-15 questionnaire)

QoR-15 Questions PART A How have you been feeling in the last 24 hours? (0 to 10, where 0 = none of the time [poor] and 10 = all of the time [excellent] Q.1 Able to breathe easily Q.2 Been able to enjoy food Q.3 Feeling rested Q.4 Have had a good sleep Q.5 Able to look after personal toilet and hygiene unaided Q.6 Able to communicate with family or friends Q.7 Getting support from hospital doctors and nurses Q.8 Able to return to work or usual home activities Q.9 Feeling comfortable and in control Q.10 Having a feeling of general well-being PART B Have you had any of the following in the last 24 hours? (10 to 0, where 10 = none of the time [excellent] and 0 = all of the time [poor]) Q.11 Moderate pain Q.12 Severe pain Q.13 Nausea or vomiting Q.14 Feeling worried or anxious Q.15 Feeling sad or depressed

up to 24 hours
Time to mobilization
Time Frame: up to 48 hours
Time to mobilization (time to first out-of-bed mobilization, in hours)
up to 48 hours
Score of sleep quality
Time Frame: up to 48 hours
Postoperative sleep quality (using NRS 0-10 (0 = no concern at all; 10 = worst ever) for the first night or the second night if the case is finished after 6pm)
up to 48 hours
In-hospital GI complications
Time Frame: up to 30 days
In-hospital GI-related composite complication (composite of ileus, obstruction, perforation, and bleeding)
up to 30 days
Non-GI-related composite complications
Time Frame: up to 30 days
Both in-hospital and 30-day non-GI-related composite complications (Complication was defined as any deviation from the normal postoperative course or organ dysfunction.[23-25] Organ-specific complications include myocardial infarction, congestive heart failure, cardiac arrest, atrial fibrillation or other types of arrhythmia, pulmonary embolus, pneumonia treated with antibiotics, respiratory failure requiring intubation, respiratory insufficiency requiring physiotherapy or oxygen therapy, stroke, transient ischemic attack, postoperative delirium or cognitive decline, renal insufficiency requiring dialysis, acute kidney injury, urinary tract infection requiring antibiotics, hepatic insufficiency, gut hypoperfusion, ileus, disseminated intravascular coagulation, and sepsis. Surgery-related complications refer to surgical site bleeding, infection, anastomotic leakage, stenosis, ischemia, or tissue necrosis.)
up to 30 days
Length of hospital stay
Time Frame: up to 30 days
Length of hospital stay, in days
up to 30 days
Rate of ICU admission
Time Frame: Up to 30 days
The percentage of patients admitted to ICU after surgery
Up to 30 days
30-day mortality
Time Frame: 30 days
30-day mortality
30 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 15, 2018

Primary Completion (Actual)

June 29, 2019

Study Completion (Actual)

July 31, 2019

Study Registration Dates

First Submitted

July 27, 2018

First Submitted That Met QC Criteria

August 17, 2018

First Posted (Actual)

August 22, 2018

Study Record Updates

Last Update Posted (Actual)

September 25, 2019

Last Update Submitted That Met QC Criteria

September 23, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Individual participant data are available to the editorial office of the journal to which the manuscript is submitted upon request.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Nausea and Vomiting

Clinical Trials on Muscular tissue oxygen saturation guided care

3
Subscribe